Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

SURVIVEiT Sarcoma Patient Stories Plus Signs & Symptoms

Sarcoma Patient Stories Plus Signs & Symptoms

July is sarcoma and bone cancer awareness month, so we want to shed some light on this particular type of cancer. According to the National Foundation for Cancer Research, because...
SURVIVEiT Have You Added This Anti-Cancer Superfood To Your Diet

Have You Added This Anti-Cancer Superfood To Your Diet?

One of our Survivor Advisory Council Members, Hayley, writes about her cancer experience on her blog revivewellness.com. She shares lots of helpful information for people who have completed cancer treatment...
SURVIVEiT A 5-Step Approach To Personalized Planning After A Cancer Diagnosis

A 5-Step Approach To Personalized Planning After A Cancer Diagnosis

Feeling overwhelmed by a cancer diagnosis? We can help. SURVIVEiT's Cancer Navigation Tool was developed by survivors and medical experts to help cancer patients and caregivers advocate for themselves. This...
SURVIVEiT Cancer Survivors Share Their Top Advice

Cancer Survivors Share Their Top Advice

June is National Cancer Survivors Month. SURVIVEiT® is made up of cancer survivors, patients, caregivers and medical professionals who are using their experiences and expertise to help those facing cancer...
SURVIVEiT The Unexpected Life After Cancer & Tools To Help Manage It

An Unexpected Life After Cancer & Tools To Help Manage It

When asked how Step 5 (LIVEiT) of our Cancer Navigation Tool played a major part in her cancer journey, this is what Ashley has to say.  ——————————Guest Blog —————————— Cancer...
SURVIVEiT Giving Week Results Blog Header (1)

2021 Giving Week Results Are In!

A BIG thank you to all of our generous donors who helped us raise $26,346 during our 2021 Giving Week. That's 105% of our goal! The inability to host events...
SURVIVEiT Guest Blog - Bladder Cancer Patient Stories Plus Signs & Symptoms

Bladder Cancer Patient Stories Plus Signs & Symptoms To Be Aware Of

May is bladder cancer awareness month, so we want to shed some light on this particular type of cancer. According to the World Bladder Cancer Patient Coalition, bladder cancer is...
SURVIVEiT Giving Week Blog Header

SURVIVEiT®’s 2021 Giving Week Is Here!

This week is our Giving Week - our biggest online fundraising week of the year. Help us personalize our Cancer Navigation Tool to more cancer types by donating today!  ...
SURVIVEiT Guest Blog - Peggy Dennis - The Tools That Allow Me To Address My Cancer With Less Fear and More Hope

The Tools That Allow Me To Address My Cancer With Less Fear and More Hope

When asked how Step 1 (TESTiT) and STEP 2 (VERIFYiT) of our Cancer Navigation Tool played a major part in her journey, this is what Peggy has to say.  ——————————Guest...
FDA_Drug_Newsroom

FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma

FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA),...
FDA_Drug_Newsroom

FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer

FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer On April 22, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients...
FDA_Drug_Newsroom

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma On April 16, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in...